Drugging tRNA aminoacylation. Issue 4 (4th May 2018)

• Record Type: Journal Article
• Authors: Ho, Joanne M.; Bakkalbasi, Erol; Söll, Dieter; Miller, Corwin A.
• Is Part Of: RNA biology. Volume 15:Issue 4/5(2018)
• Page Start: 667
• Page End: 677
• Publication Date: 2018-05-04
• Subjects: Aminoacylation -- aminoacyl tRNA synthetases -- antibiotics -- antimicrobials -- antibiotic targets -- drug development -- drug targets -- transfer RNA -- translation inhibitors; RNA -- Periodicals; Molecular biology -- Periodicals; Molecular biology; RNA; Periodicals; 572.8805
• DOI: 10.1080/15476286.2018.1429879
• Languages: English
• ISSNs: 1547-6286

Abstract

ABSTRACT: Inhibition of tRNA aminoacylation has proven to be an effective antimicrobial strategy, impeding an essential step of protein synthesis. Mupirocin, the well-known selective inhibitor of bacterial isoleucyl-tRNA synthetase, is one of three aminoacylation inhibitors now approved for human or animal use. However, design of novel aminoacylation inhibitors is complicated by the steadfast requirement to avoid off-target inhibition of protein synthesis in human cells. Here we review available data regarding known aminoacylation inhibitors as well as key amino-acid residues in aminoacyl-tRNA synthetases (aaRSs) and nucleotides in tRNA that determine the specificity and strength of the aaRS-tRNA interaction. Unlike most ligand-protein interactions, the aaRS-tRNA recognition interaction represents coevolution of both the tRNA and aaRS structures to conserve the specificity of aminoacylation. This property means that many determinants of tRNA recognition in pathogens have diverged from those of humans—a phenomenon that provides a valuable source of data for antimicrobial drug development.